clinical trial · NCT06714461
A Study of the Effectiveness of Additional Risk Minimization Measures Related to ARAVA® (Leflunomide) in Saudi Arabia
Rheumatoid ArthritisPsoriatic ArthritisLeflunomide
brief summary
The main objective of this post-authorization safety study is to assess healthcare professionals' awareness, knowledge, and behavior related to receipt and reading of the Direct Healthcare Professional Communication and educational materials for ARAVA® (leflunomide) and of the additional risk minimization measures.
started
May 5, 2025
primary completion
May 31, 2026
completion
May 31, 2026
last updated
Apr 28, 2026
official title
Post Authorization Safety Study on Assessment of Effectiveness of Additional Risk Minimization Measures Related to ARAVA® (Leflunomide) in Saudi Arabia
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol